Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Parathyroidectomy | Research

Characteristics, management and outcomes of primary hyperparathyroidism from 2009 to 2021: a single centre report from South Africa

Authors: Kamal Govind, Imran M. Paruk, Ayesha A. Motala

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Background

There has been a notable shift towards the diagnosis of less severe and asymptomatic primary hyperparathyroidism (PHPT) in developed countries. However, there is a paucity of recent data from sub-Saharan Africa (SSA), and also, no reported data from SSA on the utility of intra-operative parathyroid hormone (IO-PTH) monitoring. In an earlier study from Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa (2003–2009), majority of patients (92.9%) had symptomatic disease. The aim of this study was to evaluate the clinical profile and management outcomes of patients presenting with PHPT at IALCH.

Methods

A retrospective chart review of patients with PHPT attending the Endocrinology clinic at IALCH between July 2009 and December 2021. Clinical presentation, laboratory results, radiologic findings, surgical notes and histology were recorded.

Results

Analysis included 110 patients (87% female) with PHPT. Median age at presentation was 57 (44; 67.5) years. Symptomatic disease was present in 62.7% (n:69); 20.9% (n:23) had a history of nephrolithiasis and 7.3% (n:8) presented with previous fragility fractures. Mean serum calcium was 2.87 ± 0.34 mmol/l; median serum-PTH was 23.3 (15.59; 45.38) pmol/l, alkaline phosphatase 117.5 (89; 145.5) U/l and 25-hydroxyvitamin-D 42.9 (33.26; 62.92) nmol/l. Sestamibi scan (n:106 patients) identified an adenoma in 83.02%. Parathyroidectomy was performed on 84 patients with a cure rate of 95.2%. Reasons for conservative management (n:26) included: no current surgical indication (n:7), refusal (n:5) or deferral of surgery (n:5), loss to follow-up (n:5) and assessed as high anaesthetic risk (n:4). IO-PTH measurements performed on 28 patients indicated surgical success in 100%, based on Miami criteria. Histology confirmed adenoma in 88.1%, hyperplasia in 7.1% and carcinoma in 4.8%. Post-operative hypocalcaemia developed in 30 patients (35.7%), of whom, 14 developed hungry bone syndrome (HBS). In multivariate analysis, significant risk factors associated with HBS included male sex (OR 7.01; 95% CI 1.28, 38.39; p 0.025) and elevated pre-operative PTH (OR 1.01; 95% CI 1.00, 1.02; p 0.008).

Conclusions

The proportion of asymptomatic PHPT has increased at this centre over the past decade but symptomatic disease remains the dominant presentation. Parathyroidectomy is curative in the majority of patients. IO-PTH monitoring is valuable in ensuring successful surgery.
Literature
1.
go back to reference Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism Lancet. 2018;391(10116):168–78.CrossRefPubMed Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism Lancet. 2018;391(10116):168–78.CrossRefPubMed
2.
go back to reference Zhu CY, Sturgeon C, Yeh MW. Diagnosis and management of primary hyperparathyroidism. JAMA. 2020. Zhu CY, Sturgeon C, Yeh MW. Diagnosis and management of primary hyperparathyroidism. JAMA. 2020.
3.
go back to reference Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Reviews Endocrinol. 2018;14(2):115–25.CrossRef Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Reviews Endocrinol. 2018;14(2):115–25.CrossRef
5.
go back to reference Yadav SK, Mishra SK, Mishra A, Mayilvagnan S, Chand G, Agarwal G, et al. Changing Profile of primary hyperparathyroidism over two and half decades: a study in Tertiary Referral Center of North India. World J Surg. 2018;42(9):2732–7.CrossRefPubMed Yadav SK, Mishra SK, Mishra A, Mayilvagnan S, Chand G, Agarwal G, et al. Changing Profile of primary hyperparathyroidism over two and half decades: a study in Tertiary Referral Center of North India. World J Surg. 2018;42(9):2732–7.CrossRefPubMed
6.
go back to reference Sun B, Guo B, Wu B, Kang J, Deng X, Zhang Z et al. Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016. Osteoporosis International: A Journal established as result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2018;29(3):635–42. Sun B, Guo B, Wu B, Kang J, Deng X, Zhang Z et al. Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016. Osteoporosis International: A Journal established as result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2018;29(3):635–42.
7.
go back to reference Rojas AP, Fain K, Peiris AN. Resolution of hypercalcemia in primary hyperparathyroidism with vitamin D replacement. Proceedings (Baylor University Medical Center). 2019;33(1):40 – 1. Rojas AP, Fain K, Peiris AN. Resolution of hypercalcemia in primary hyperparathyroidism with vitamin D replacement. Proceedings (Baylor University Medical Center). 2019;33(1):40 – 1.
8.
go back to reference Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017;55(1):3–5.CrossRefPubMed Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017;55(1):3–5.CrossRefPubMed
9.
go back to reference Khan ZF, Lew JI. Intraoperative parathyroid hormone monitoring in the Surgical Management of sporadic primary hyperparathyroidism. Endocrinol Metabolism (Seoul Korea). 2019;34(4):327–39.CrossRef Khan ZF, Lew JI. Intraoperative parathyroid hormone monitoring in the Surgical Management of sporadic primary hyperparathyroidism. Endocrinol Metabolism (Seoul Korea). 2019;34(4):327–39.CrossRef
10.
go back to reference Paruk IM, Esterhuizen TM, Maharaj S, Pirie FJ, Motala AA. Characteristics, management and outcome of primary hyperparathyroidism in South Africa: a single-centre experience. Postgrad Med J. 2013;89(1057):626–31.CrossRefPubMed Paruk IM, Esterhuizen TM, Maharaj S, Pirie FJ, Motala AA. Characteristics, management and outcome of primary hyperparathyroidism in South Africa: a single-centre experience. Postgrad Med J. 2013;89(1057):626–31.CrossRefPubMed
11.
go back to reference Budge M, Conradie W, Beviss-Challinor K, Martin L, Conradie M, Coetzee A. Bone health in patients undergoing surgery for primary hyperparathyroidism at Tygerberg Hospital, Cape Town, South Africa. J Endocrinol Metabolism Diabetes South Afr. 2021;26(1):16–23.CrossRef Budge M, Conradie W, Beviss-Challinor K, Martin L, Conradie M, Coetzee A. Bone health in patients undergoing surgery for primary hyperparathyroidism at Tygerberg Hospital, Cape Town, South Africa. J Endocrinol Metabolism Diabetes South Afr. 2021;26(1):16–23.CrossRef
12.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A New equation to Estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A New equation to Estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral
13.
go back to reference Khan AA, Khatun Y, Walker A, Jimeno J, Hubbard JG. Role of intraoperative PTH monitoring and surgical approach in primary hyperparathyroidism. Annals Med Surg. 2015;4(3):301–5.CrossRef Khan AA, Khatun Y, Walker A, Jimeno J, Hubbard JG. Role of intraoperative PTH monitoring and surgical approach in primary hyperparathyroidism. Annals Med Surg. 2015;4(3):301–5.CrossRef
14.
go back to reference Witteveen JE, vTS, Romijn JA, Hamdy NA. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45–53.CrossRefPubMed Witteveen JE, vTS, Romijn JA, Hamdy NA. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45–53.CrossRefPubMed
15.
go back to reference Yadav SK, Johri G, Bichoo RA, Jha CK, Kintu-Luwaga R, Mishra SK. Primary hyperparathyroidism in developing world: a systematic review on the changing clinical profile of the disease. Archives Endocrinol Metabolism. 2020;64. Yadav SK, Johri G, Bichoo RA, Jha CK, Kintu-Luwaga R, Mishra SK. Primary hyperparathyroidism in developing world: a systematic review on the changing clinical profile of the disease. Archives Endocrinol Metabolism. 2020;64.
16.
go back to reference Lin X, Fan Y, Zhang Z, Yue H. Clinical characteristics of primary hyperparathyroidism: 15-Year experience of 457 patients in a single Center in China. Front Endocrinol. 2021;12. Lin X, Fan Y, Zhang Z, Yue H. Clinical characteristics of primary hyperparathyroidism: 15-Year experience of 457 patients in a single Center in China. Front Endocrinol. 2021;12.
17.
go back to reference Ahn DK. Ji. Role and recent Trend of intraoperative parathyroid hormone monitoring during parathyroidectomy in patients with primary hyperparathyroidism. Korean J Otorhinolaryngology-Head Neck Surg. 2022;65:253–9.CrossRef Ahn DK. Ji. Role and recent Trend of intraoperative parathyroid hormone monitoring during parathyroidectomy in patients with primary hyperparathyroidism. Korean J Otorhinolaryngology-Head Neck Surg. 2022;65:253–9.CrossRef
18.
go back to reference Hargitai L, Bereuter CM, Dunkler D, Geroldinger A, Scheuba C, Niederle B, et al. The value of intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism and varying baseline parathyroid hormone levels. BJS Open. 2022;6(6):zrac118.CrossRefPubMedPubMedCentral Hargitai L, Bereuter CM, Dunkler D, Geroldinger A, Scheuba C, Niederle B, et al. The value of intraoperative parathyroid hormone monitoring in patients with primary hyperparathyroidism and varying baseline parathyroid hormone levels. BJS Open. 2022;6(6):zrac118.CrossRefPubMedPubMedCentral
19.
go back to reference Graceffa G, Cipolla C, Calagna S, Contino S, Melfa G, Orlando G, et al. Interpretation of intraoperative parathyroid hormone monitoring according to the Rome criterion in primary hyperparathyroidism. Sci Rep. 2022;12(1):3333.CrossRefPubMedPubMedCentral Graceffa G, Cipolla C, Calagna S, Contino S, Melfa G, Orlando G, et al. Interpretation of intraoperative parathyroid hormone monitoring according to the Rome criterion in primary hyperparathyroidism. Sci Rep. 2022;12(1):3333.CrossRefPubMedPubMedCentral
20.
go back to reference Meng L, Liu S, Al-Dayyeni A, Sheng Z, Zhou Z, Wang X. Comparison of initial clinical presentations between primary hyperparathyroidism patients from New Brunswick and Changsha. Int J Endocrinol. 2018;2018:6282687.CrossRefPubMedPubMedCentral Meng L, Liu S, Al-Dayyeni A, Sheng Z, Zhou Z, Wang X. Comparison of initial clinical presentations between primary hyperparathyroidism patients from New Brunswick and Changsha. Int J Endocrinol. 2018;2018:6282687.CrossRefPubMedPubMedCentral
21.
go back to reference Liu J-m, Cusano NE, Silva BC, Zhao L, He X-y, Tao B, et al. Primary hyperparathyroidism: a tale of two cities revisited — New York and Shanghai. Bone Res. 2013;1(1):162–9.CrossRefPubMedPubMedCentral Liu J-m, Cusano NE, Silva BC, Zhao L, He X-y, Tao B, et al. Primary hyperparathyroidism: a tale of two cities revisited — New York and Shanghai. Bone Res. 2013;1(1):162–9.CrossRefPubMedPubMedCentral
22.
go back to reference Al-Saleh Y, AlSohaim A, AlAmoudi R, AlQarni A, Alenezi R, Mahdi L, et al. Primary hyperparathyroidism in Saudi Arabia revisited: a multi-centre observational study. BMC Endocr Disorders. 2022;22(1):155.CrossRef Al-Saleh Y, AlSohaim A, AlAmoudi R, AlQarni A, Alenezi R, Mahdi L, et al. Primary hyperparathyroidism in Saudi Arabia revisited: a multi-centre observational study. BMC Endocr Disorders. 2022;22(1):155.CrossRef
23.
go back to reference Pawlowska MCN. An overview of normocalcemic primary hyperparathyroidism. Current opinion in Endocrinology. Diabetes Obes. 2015;22(6):413–21. Pawlowska MCN. An overview of normocalcemic primary hyperparathyroidism. Current opinion in Endocrinology. Diabetes Obes. 2015;22(6):413–21.
24.
go back to reference Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE-H, Marcocci C, Minisola S et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. Journal of Bone and Mineral Research. 2022;37(11):2293 – 314. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE-H, Marcocci C, Minisola S et al. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. Journal of Bone and Mineral Research. 2022;37(11):2293 – 314.
25.
go back to reference Schini M, Jacques R, Oakes E, Peel N, Walsh J, Eastell R. Normocalcemic hyperparathyroidism: study of its prevalence and natural history. The Journal of Clinical Endocrinology & Metabolism; 2020. Schini M, Jacques R, Oakes E, Peel N, Walsh J, Eastell R. Normocalcemic hyperparathyroidism: study of its prevalence and natural history. The Journal of Clinical Endocrinology & Metabolism; 2020.
26.
go back to reference Walker MDCE, Lee JA, et al. Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab. 2015;100(9):3443–51.CrossRefPubMedPubMedCentral Walker MDCE, Lee JA, et al. Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab. 2015;100(9):3443–51.CrossRefPubMedPubMedCentral
27.
go back to reference Şengül Ayçiçek GAB, Şahin M, Emral R, Erdoğan MF, Güllü S, Başkal N, Çorapçıoğlu D. The impact of vitamin D deficiency on clinical, biochemical and metabolic parameters in primary hyperparathyroidism. Endocrinol Diabetes Nutr (Engl Ed). 2023;70(1):56–62.PubMed Şengül Ayçiçek GAB, Şahin M, Emral R, Erdoğan MF, Güllü S, Başkal N, Çorapçıoğlu D. The impact of vitamin D deficiency on clinical, biochemical and metabolic parameters in primary hyperparathyroidism. Endocrinol Diabetes Nutr (Engl Ed). 2023;70(1):56–62.PubMed
28.
go back to reference Walker MD, Cong E, Lee JA, Kepley A, Zhang C, McMahon DJ, et al. Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metabolism. 2015;100(9):3443–51.CrossRef Walker MD, Cong E, Lee JA, Kepley A, Zhang C, McMahon DJ, et al. Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metabolism. 2015;100(9):3443–51.CrossRef
29.
go back to reference Udelsman RLZ, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253(3):585–91.CrossRefPubMed Udelsman RLZ, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253(3):585–91.CrossRefPubMed
31.
go back to reference Mallikarjuna VM, Vivek and Ayyar, Vageesh and Bantwal, Ganapathy and Ganesh, Vaishnavi and George, Belinda and Hemanth, GN and, Vinotha P. Five-year Retrospective Study on Primary Hyperparathyroidism in South India: Emerging Roles of Minimally Invasive Parathyroidectomy and Preoperative Localization with Methionine Positron Emission Tomography-Computed Tomography Scan. Indian Journal of Endocrinology and Metabolism. 2018;22:355. Mallikarjuna VM, Vivek and Ayyar, Vageesh and Bantwal, Ganapathy and Ganesh, Vaishnavi and George, Belinda and Hemanth, GN and, Vinotha P. Five-year Retrospective Study on Primary Hyperparathyroidism in South India: Emerging Roles of Minimally Invasive Parathyroidectomy and Preoperative Localization with Methionine Positron Emission Tomography-Computed Tomography Scan. Indian Journal of Endocrinology and Metabolism. 2018;22:355.
32.
go back to reference Tay D, Das JP, Yeh R. Preoperative localization for primary hyperparathyroidism: a clinical review. Biomedicines. 2021;9(4). Tay D, Das JP, Yeh R. Preoperative localization for primary hyperparathyroidism: a clinical review. Biomedicines. 2021;9(4).
33.
go back to reference Johnson NA, Tublin ME, Ogilvie JB. Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. Am J Roentgenol. 2007;188(6):1706–15.CrossRef Johnson NA, Tublin ME, Ogilvie JB. Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. Am J Roentgenol. 2007;188(6):1706–15.CrossRef
34.
go back to reference Abd Elhameed Elsayed W, Ali RA. Efficacy of Scintigraphy, Ultrasound and both Scintigraphy and Ultrasonography in Preoperative Detection and localization of primary hyperparathyroidism. Cureus. 2019;11(6):e4960.PubMedPubMedCentral Abd Elhameed Elsayed W, Ali RA. Efficacy of Scintigraphy, Ultrasound and both Scintigraphy and Ultrasonography in Preoperative Detection and localization of primary hyperparathyroidism. Cureus. 2019;11(6):e4960.PubMedPubMedCentral
35.
go back to reference Jakubauskas MB, Strupas V. Kęstutis. Risk factors of developing the hungry bone syndrome after parathyroidectomy for primary hyperparathyroidism. Acta Med Lituanica. 2018;25. Jakubauskas MB, Strupas V. Kęstutis. Risk factors of developing the hungry bone syndrome after parathyroidectomy for primary hyperparathyroidism. Acta Med Lituanica. 2018;25.
36.
go back to reference Kaya C, Tam AA, Dirikoç A, Kılıçyazgan A, Kılıç M, Türkölmez Ş et al. Hypocalcemia development in patients operated for primary hyperparathyroidism: can it be predicted preoperatively? Archives Endocrinol Metabolism. 2016;60. Kaya C, Tam AA, Dirikoç A, Kılıçyazgan A, Kılıç M, Türkölmez Ş et al. Hypocalcemia development in patients operated for primary hyperparathyroidism: can it be predicted preoperatively? Archives Endocrinol Metabolism. 2016;60.
37.
go back to reference Guillén Martínez AJ, Smilg Nicolás C, Moraleda Deleito J, Guillén Martínez S, García-Purriños García F. Risk factors and evolution of calcium and parathyroid hormone levels in hungry bone syndrome after parthyroidectomy for primary hyperparathyroidism. Endocrinología Diabetes Y Nutrición (English ed). 2020;67(5):310–6. Guillén Martínez AJ, Smilg Nicolás C, Moraleda Deleito J, Guillén Martínez S, García-Purriños García F. Risk factors and evolution of calcium and parathyroid hormone levels in hungry bone syndrome after parthyroidectomy for primary hyperparathyroidism. Endocrinología Diabetes Y Nutrición (English ed). 2020;67(5):310–6.
38.
go back to reference Chandran M, Bilezikian JP, Salleh NM, Ying H, Lau J, Lee J, et al. Hungry bone syndrome following parathyroidectomy for primary hyperparathyroidism in a developed country in the Asia Pacific. A cohort study. Osteoporos Sarcopenia. 2022;8(1):11–6.CrossRefPubMedPubMedCentral Chandran M, Bilezikian JP, Salleh NM, Ying H, Lau J, Lee J, et al. Hungry bone syndrome following parathyroidectomy for primary hyperparathyroidism in a developed country in the Asia Pacific. A cohort study. Osteoporos Sarcopenia. 2022;8(1):11–6.CrossRefPubMedPubMedCentral
39.
go back to reference Lee IT, Sheu WH-H, Tu S-T, Kuo S-W, Pei D. Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. J Bone Miner Metab. 2006;24(3):255–8.CrossRefPubMed Lee IT, Sheu WH-H, Tu S-T, Kuo S-W, Pei D. Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. J Bone Miner Metab. 2006;24(3):255–8.CrossRefPubMed
40.
go back to reference Mayilvaganan SVSH, Shivaprasad C. Preoperative zoledronic acid therapy prevent hungry bone syndrome in patients with primary hyperparathyroidism. Indian J Endocrinol Metab. 2017;21(1):76–9.CrossRefPubMedPubMedCentral Mayilvaganan SVSH, Shivaprasad C. Preoperative zoledronic acid therapy prevent hungry bone syndrome in patients with primary hyperparathyroidism. Indian J Endocrinol Metab. 2017;21(1):76–9.CrossRefPubMedPubMedCentral
41.
go back to reference França TCGL, Pinho J, Diniz ET, Andrade LD, Lucena CS, Beserra SR, Asano NM, Duarte AP, Bandeira F. Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica. Rev Bras Reumatol. 2011;51(2):131–7.CrossRefPubMed França TCGL, Pinho J, Diniz ET, Andrade LD, Lucena CS, Beserra SR, Asano NM, Duarte AP, Bandeira F. Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica. Rev Bras Reumatol. 2011;51(2):131–7.CrossRefPubMed
42.
go back to reference Pal RGA, Bhadada SK. Role of bisphosphonates in the Prevention of Postoperative Hungry Bone Syndrome in primary hyperparathyroidism: a Meta-analysis and need for randomized controlled trials. Drug Res (Stuttg). 2021;71(2):108–9.CrossRefPubMed Pal RGA, Bhadada SK. Role of bisphosphonates in the Prevention of Postoperative Hungry Bone Syndrome in primary hyperparathyroidism: a Meta-analysis and need for randomized controlled trials. Drug Res (Stuttg). 2021;71(2):108–9.CrossRefPubMed
43.
go back to reference Lu S, Gong M, Zha Y, Cui A, Chen C, Sun W, et al. Identification of independent factors affecting bone mineral density after successful parathyroidectomy for symptomatic hyperparathyroidism. BMC Endocr Disorders. 2020;20(1):141.CrossRef Lu S, Gong M, Zha Y, Cui A, Chen C, Sun W, et al. Identification of independent factors affecting bone mineral density after successful parathyroidectomy for symptomatic hyperparathyroidism. BMC Endocr Disorders. 2020;20(1):141.CrossRef
44.
go back to reference Lu SG, Maoqi; Zha Y, Cui A, Chen C, Yang H, Sun W, Hua K, Tian W. Jiang, Xieyuan. Changes in bone mineral density after parathyroidectomy in patients with moderate to severe primary hyperparathyroidism. J Int Med Res. 2020;48. Lu SG, Maoqi; Zha Y, Cui A, Chen C, Yang H, Sun W, Hua K, Tian W. Jiang, Xieyuan. Changes in bone mineral density after parathyroidectomy in patients with moderate to severe primary hyperparathyroidism. J Int Med Res. 2020;48.
Metadata
Title
Characteristics, management and outcomes of primary hyperparathyroidism from 2009 to 2021: a single centre report from South Africa
Authors
Kamal Govind
Imran M. Paruk
Ayesha A. Motala
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-024-01583-8

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.